Tag: transarterial chemoembolization
First release RETNET data show no difference in progression-free survival between...
New data from a prospective, multicentre randomised controlled trial show similar hepatic progression-free survival (hPFS) using bland transarterial embolization (TAE) or transarterial chemoembolization (TACE)...
New analysis benchmarks survival rates in unresectable intrahepatic cholangiocarcinoma patients undergoing...
Updating on a previous meta-analysis, new data which pooled survival estimates of patients undergoing transarterial radioembolization (TARE) has shown the treatment to be a...
‘A new narrative’: TACE in the age of Y90 and immunotherapy
Hotly debated across the Society of Interventional Oncology (SIO; 25–29 January 2024, Long Beach, USA) annual conference programme, speakers took to the stage to...
HKUMed discovers new trimodality therapy for locally advanced liver cancer
A phase II clinical study on a trimodality therapy (START-FIT), conducted by the Departments of Surgery and Clinical Oncology, School of Clinical Medicine, University...
Conventional transarterial chemoembolization more cost-effective than drug-eluting embolic TACE
Compared with doxorubicin-loaded drug-eluting embolic transarterial chemoembolization (DEE-TACE), conventional transarterial chemoembolization (cTACE) yielded a higher number of quality-adjusted life years (QALY) at a lower...
International survey reveals high variability in TACE technique
Transarterial chemoembolization (TACE) is a mainstay of locoregional treatment for hepatocellular carcinoma (HCC) in the intermediate stage. “The technique for this procedure, however, continues...